In June this year, we shared the first of our regular quarterly progress updates for the Shake It Up Australia Foundation. Since then, we’ve seen ma...
In December of last year, I took on the role as CEO of Shake It Up Australia, after nearly six years as Executive General Manager. At the time, I shar...
On Saturday, February 11th, we celebrate the International Day of Women and Girls in Science, which was established by the United Nations General Asse...
The U.S. Food and Drug Administration (FDA) last week approved lecanemab (brand name Leqembi) developed by Eisai Co Ltd. and Biogen Inc. for people w...
Our partners at The Michael J Fox Foundation take a walk down memory lane as we review recent research highlights and milestones in the 20-year histor...
Recent interviews conducted by Shake It Up supporter Maree Faulkner with 21 Australians living with Parkinson’s explored the impact of their diagnos...
Last month, CEO, of The Michael J. Fox Foundation (MJFF), Todd Sherer, PhD, led a panel at the Precision Medicine Leaders Summit called “The Power o...
Two recent papers outline the progression of Parkinson’s disease (PD) movement or motor symptoms in distinct study populations. While these findings...
2017 marks the 200th anniversary of James Parkinson’s description of the disease that now bears his name and that affects an estimated 5 million peo...
Parkinson’s disease (PD) is a complex and varied disorder with many different potential motor and non-motor symptoms. Early on, it can sometimes be ...
Glutathione is made naturally by the body but is also available in certain foods and over-the-counter supplements. Glutathione levels decrease with ag...
Over the past few months, one particular Alzheimer’s disease (AD) drug target has repeatedly been in the news for all the wrong reasons: a protein c...